In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $1.24 in the prior trading day, Inozyme Pharma Inc (NASDAQ: INZY) closed at $1.15, down -7.26%. In other words, the price has decreased by -$7.26 from its previous closing price. On the day, 0.58 million shares were traded.
Ratios:
Our goal is to gain a better understanding of INZY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.56 and its Current Ratio is at 3.56. In the meantime, Its Debt-to-Equity ratio is 0.81 whereas as Long-Term Debt/Eq ratio is at 0.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on December 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $26.
On September 12, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’25 when Treco Douglas A sold 8,819 shares for $0.89 per share. The transaction valued at 7,849 led to the insider holds 41,046 shares of the business.
Stock Price History:
Over the past 52 weeks, INZY has reached a high of $6.24, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is 10.48%, while the 200-Day Moving Average is calculated to be -62.13%.
Shares Statistics:
A total of 64.24M shares are outstanding, with a floating share count of 43.75M. Insiders hold about 32.23% of the company’s shares, while institutions hold 59.12% stake in the company.
